Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/303% below fair value
$8.36−0.08 (-0.95%)
Close on Nov 13, 2026Market cap $237.62MP/E –Yield –
Arcturus Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Arcturus Therapeutics's enterprise value was $73.14M on Nov 11, 2026, against $4.57M a year earlier. Over the last 5 years it ranged from -$47.66M to $764.17M, with a median of $247.17M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $73.14M | – |
| 2025 | Dec 31, 2025 | -$13.41M | -106.0% |
| 2024 | Dec 31, 2024 | $222.44M | -59.6% |
| 2023 | Dec 29, 2023 | $550.66M | +102.9% |
| 2022 | Dec 30, 2022 | $271.37M | -56.4% |
| 2021 | Dec 31, 2021 | $622.12M | -19.2% |
| 2020 | Dec 31, 2020 | $769.69M | +667.7% |
| 2019 | Dec 31, 2019 | $100.26M | – |
See a number that looks wrong?